News & Events

The information in our press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.

Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering

SEATTLE, April 22, 2021 — Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the pricing of its…

READ MORE

IMPEL NEUROPHARMA ANNOUNCES KEY MANAGEMENT TEAM APPOINTMENTS AS COMPANY ADVANCES TOWARD COMMERCIALIZATION IN 2021

Leonard S. Paolillo Appointed as Chief Commercial Officer, Gerald F. Penn Appointed as Vice President, Market Access & Trade Significant Leadership Experience Continues Build Out of Impel’s Commercial Strategy, Infrastructure and Market Access Capabilities as Company Advances Go-To-Market Strategy for…

READ MORE

IMPEL NEUROPHARMA PARTNERS WITH VEEVA SYSTEMS TO BUILD INTEGRATED, DIGITAL-FIRST COMMERCIAL FOUNDATION

Impel adopting Veeva software, data, and consultingto accelerate pre-launch planning and digital-first commercial execution SEATTLE and PLEASANTON, CA — February 10, 2021 — Impel NeuroPharma and Veeva Systems (NYSE: VEEV) today announced a strategic partnership as Impel continues advancing its…

READ MORE

IMPEL NEUROPHARMA ANNOUNCES U.S. FOOD & DRUG ADMINISTRATION ACCEPTANCE OF NEW DRUG APPLICATION FOR INP104 FOR THE ACUTE TREATMENT OF MIGRAINE

FDA Conditionally Accepts Trade Name, TRUDHESA™, Pending Approval of the NDA, and Sets PDUFA Goal Date of September 6, 2021 Company’s Lead Candidate is Based on Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology, and is the First and Only Delivery…

READ MORE